2020 ASCO Virtual Direct™ Highlights

 

Avatar

PARPi Efficacy in Recurrent Platinum Sensitive Ovarian Cancer: Is Olaparib More Effective as Mono or Combination Therapy?

By Total Health 1201 Videos FEATURING Carolyn Muller
118 views
October 13, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

23:46
AstraZeneca Oncology

First-line Maintenance Treatment Option in Patients With HRD-Positiv…

Feat. S. Lewin

Featured Video

23:14
AstraZeneca Oncology

Management Strategies for Nausea and Vomiting in First-line Maintena…

Feat. D. Czel, C. Arn
GYN
19:19
Total Health

2020 ASCO Update on Recurrent Ovarian Cancer: Does Secondary Cytored…

Feat. C. Muller
07:40
Total Health

2020 ASCO Update on Platinum Sensitive, Relapsed Ovarian Cancer: Is …

Feat. C. Muller
09:08
Total Health

PARPi Efficacy in Recurrent Platinum Sensitive Ovarian Cancer: Is Ol…

Feat. C. Muller